---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-119014"
form_type: "8-K"
ticker: "LAB"
cik: "0001162194"
company_name: "STANDARD BIOTOOLS INC."
filed_at: "2024-10-30T23:59:59+00:00"
generated_at: "2026-05-30T08:01:15.655621+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Standard BioTools Q3 revenue $45M, net loss improves 34.6% YoY; reaffirms FY2024 outlook

## Summary
- Q3 2024 revenue $45.0M (-5% YoY pro forma); net loss $26.9M improved from $41.2M loss YoY.
- Adjusted EBITDA loss $14.2M vs $28.2M loss YoY, a 49.6% improvement; merger synergies $80M on track for 2025.
- Consumables revenue up 13% to $14.0M; Instruments down 42% to $5.6M due to capital constraints, especially China.
- FY2024 revenue guidance reaffirmed at $170M-$175M; path to adjusted EBITDA break-even in 2026.
- Cash and short-term investments $367.6M; gross margin 51.7% (42.5% YoY), non-GAAP gross margin 56.9%.

## SEC filing metadata
- accession: 0000950170-24-119014
- form_type: 8-K
- ticker: LAB
- cik: 0001162194
- company_name: STANDARD BIOTOOLS INC.
- filed_at: 2024-10-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1162194/000095017024119014/0000950170-24-119014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1162194/000095017024119014/lab-20241030.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-119014
- JSON: https://secwatch.observer/filing/0000950170-24-119014.json
- Plain text: https://secwatch.observer/filing/0000950170-24-119014.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.